Screener
Recursion Pharmaceuticals, Inc. RXRX Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 6:32 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001601830-26-000078
FAQ
- What is Recursion Pharmaceuticals, Inc.'s effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents?
- Recursion Pharmaceuticals, Inc. (RXRX) reported effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents of -$3.83M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents decreased by 179.3% year-over-year, from $4.83M to -$3.83M.
- What does effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents mean?
- Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude